Atara Biotherapeutics (NASDAQ:ATRA) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Atara Biotherapeutics and Titan Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atara Biotherapeutics||N/A||N/A||-$230.70 million||($5.27)||-3.08|
|Titan Pharmaceuticals||$6.62 million||1.01||-$9.02 million||($0.79)||-0.54|
Titan Pharmaceuticals has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Atara Biotherapeutics and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Atara Biotherapeutics has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Atara Biotherapeutics and Titan Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Atara Biotherapeutics currently has a consensus target price of $39.60, indicating a potential upside of 143.84%. Titan Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 841.18%. Given Titan Pharmaceuticals’ higher probable upside, analysts clearly believe Titan Pharmaceuticals is more favorable than Atara Biotherapeutics.
Insider & Institutional Ownership
91.8% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 5.4% of Titan Pharmaceuticals shares are owned by institutional investors. 7.0% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 6.5% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Atara Biotherapeutics beats Titan Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.